Alzamend Neuro, Inc. Overview
Pro stress-test →Alzamend Neuro is a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's, bipolar disorder, major depressive disorder, and post-traumatic stress disorder. As a pre-revenue clinical-stage biopharmaceutical company, Alzamend Neuro reported no product revenue for the three and nine months ended January 31, 2026.
Strategic Profile
Pro stress-test →The company's lead candidate AL001 demonstrated in a Phase II trial that it meets bioequivalence standards while showing numerically superior lithium delivery to the brain compared to standard lithium carbonate across all 26 measured brain regions. The pipeline consists of AL001—a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, salicylate and L-proline—and ALZN002, a patented cell-based therapeutic vaccine approach.
Competitive Landscape
Pro stress-test →Alzamend competes in the Alzheimer's disease and psychiatric disorder treatment market against established players developing immunotherapy (Eli Lilly's donanemab, Biogen's aducanumab) and lithium-based therapies. Its differentiation centers on superior brain delivery via ionic cocrystal formulation and a cell-based vaccine approach (ALZN002) offering potential dosing and cost advantages versus passive-immunity antibody therapies. The pre-revenue stage and early clinical profile position it as a speculative long-term play rather than an immediate competitive threat to marketed products.
Industry Context
Alzamend Neuro, Inc. operates in Clinical-stage neuropsychiatric therapeutics.
Key facts
Founded: 2016 · Headquarters: Atlanta, Georgia, US · Employees: Unknown · Revenue: $0 (pre-revenue clinical-stage) · Market cap: Approximately $100M–$300M (micro-cap)